Please ensure Javascript is enabled for purposes of website accessibility

Pfizer Versus Moderna: Which Is Leading U.S. Vaccine Rollout?

By Adria Cimino - Updated Apr 1, 2021 at 8:12AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

These two companies and Johnson & Johnson may vaccinate the entire population.

In this Motley Fool Live video recorded on March 26, 2021, healthcare and cannabis bureau chief Corinne Cardina and Fool.com contributor Adria Cimino discuss how Pfizer (PFE 3.59%), Moderna (MRNA -4.97%), and Johnson & Johnson (JNJ 1.75%) are faring in the U.S. vaccine rollout.

Corinne Cardina: We are now three months in to the vaccine rollout. Can't believe that. I remember when we were talking about, ''Who's going to have the first vaccine authorized?'' But at this point, we have three authorized vaccines in the U.S. Can you give us the latest update on the U.S. rollout and are we on a good trajectory?

Adria Cimino: Sure. Well, more than 47 million Americans are fully vaccinated now. That's 14% of the population. We also have more than 87 million with at least one dose. That's 26% of the population. If we want to see how each company is doing, we have numbers on that as well. We have 23 million fully vaccinated by Pfizer, 21 million fully vaccinated by Moderna, and 2 million by Johnson & Johnson. Of course, we have to keep in mind that Johnson & Johnson, they were most recently authorized, so they got in there a little bit later than the other two. And also it's a one-dose vaccine. So, President Biden bought enough doses of Pfizer and Moderna to vaccinate the entire U.S. population, but he still ordered more Johnson & Johnson. Johnson & Johnson, as you can see, is still being used. So really going after it very aggressively. The most recently announced goal is 200 million doses given in the first [100 days] of Biden's presidency -- that's the goal. We'll see if he can get there, but so far so good.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Moderna, Inc. Stock Quote
Moderna, Inc.
MRNA
$136.25 (-4.97%) $-7.13
Pfizer Inc. Stock Quote
Pfizer Inc.
PFE
$52.47 (3.59%) $1.82
Johnson & Johnson Stock Quote
Johnson & Johnson
JNJ
$176.98 (1.75%) $3.04

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
331%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/20/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.